Granules India Limited — Updates, 18-10-2024: Press Release

Granules India Limited announced the U.S. FDA's approval of its Abbreviated New Drug Application for Bupropion Hydrochloride Extended-Release Tablets in 100 mg, 150 mg, and 200 mg dosages. This marks an important milestone in expanding Granules' U.S. market presence, enhancing its product portfolio to meet global healthcare needs. With this approval, Granules now holds a total of 67 ANDA approvals from the FDA.